Evidence map›Paper›PMID 31649134›Full record

Trial reportThe oncologist2020

Updated Survival Data for a Phase I/II Study of Carboplatin plus Nab-Paclitaxel and Concurrent Radiotherapy in Patients with Locally Advanced Non-Small Cell Lung Cancer.

Yuko Tsuchiya-Kawano, Tomonari Sasaki, Hiroyuki Yamaguchi, Katsuya Hirano, Atsushi Horiike, Miyako Satouchi, Shinobu Hosokawa, Ryotaro Morinaga, Kazutoshi Komiya, Koji Inoue and 8 more

Abstract readClinical Trial, Phase IClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The oncologist, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Trial
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Yuko Tsuchiya-KawanoDepartment of Respiratory Medicine, Kitakyushu Municipal Medical Center, Kitakyushu, Japan.
Tomonari SasakiDepartment of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Hiroyuki YamaguchiDepartment of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Katsuya HiranoDepartment of Respiratory Medicine, Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Japan.
Atsushi HoriikeDepartment of Thoracic Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
Miyako SatouchiDepartment of Thoracic Oncology, Hyogo Cancer Center, Akashi, Japan.
Shinobu HosokawaDepartment of Respiratory Medicine, Japanese Red Cross Okayama Hospital, Okayama, Japan.
Ryotaro MorinagaDepartment of Thoracic Medical Oncology, Oita Prefectural Hospital, Oita, Japan.
Kazutoshi KomiyaDivision of Hematology, Respiratory Medicine, and Oncology, Saga University Hospital, Saga, Japan.
Koji InoueDepartment of Respiratory Medicine, Kitakyushu Municipal Medical Center, Kitakyushu, Japan.
Yuka FujitaDepartment of Respiratory Medicine, National Hospital Organization Asahikawa Medical Center, Asahikawa, Japan.
Ryo ToyozawaDepartment of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Japan.
Tomoki KimuraDepartment of Respiratory Medicine and Allergy, Tosei General Hospital, Seto, Japan.
Kosuke TakahashiDepartment of Respiratory Medicine, Anjo Kosei Hospital, Anjo, Japan.
Kazuo NishikawaDepartment of Medical Oncology and Hematology, Oita University Faculty of Medicine, Oita, Japan.
Junji KishimotoCenter for Clinical and Translational Research, Kyushu University Hospital, Fukuoka, Japan.
Yoichi NakanishiKitakyushu City Hospital Organization, Kitakyushu, Japan.
Isamu OkamotoResearch Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.ORCID 0000-0002-7587-6096

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

lessons learnedUpdated survival data for a phase I/II study of carboplatin plus nab-paclitaxel and concurrent radiotherapy were collected. In the group of 58 patients who were enrolled at 14 institutions in Japan, the median overall survival was not reached and the 2-year overall survival rate was 66.1% (95% confidence interval, 52.1%-76.8%). Results reveal encouraging feasibility and activity for this regimen.

backgroundWe report the updated survival data for a phase I/II study of carboplatin plus nab-paclitaxel (nab-P/C) and concurrent radiotherapy (CRT) in patients with locally advanced non-small cell lung cancer (NSCLC).

methodsIndividuals between 20 and 74 years of age with unresectable NSCLC of stage IIIA or IIIB and a performance status of 0 or 1 were eligible for the study. Patients received weekly nab-paclitaxel at 50 mg/m

resultsBetween October 2014 and November 2016, 58 patients were enrolled at 14 institutions in Japan, with 56 of these individuals being evaluable for treatment efficacy and safety. At the median follow-up time of 26.0 months (range, 4.0-49.6 months), the median overall survival (OS) was not reached (95% confidence interval [CI], 25.3 months to not reached) and the 2-year OS rate was 66.1% (95% CI, 52.1%-76.8%). The median PFS was 11.8 months (95% CI, 8.2-21.0 months), and the 2-year PFS rate was 35.9% (95% CI, 23.1%-48.9%). Subgroup analysis according to tumor histology or patient age revealed no differences in median PFS or OS. Long-term follow-up of toxicities did not identify new safety signals, and no treatment-related deaths occurred during the study period.

conclusionConcurrent chemoradiation with nab-P/C was safe and provided a long-term survival benefit for patients with locally advanced NSCLC.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsAlbuminsAntineoplastic Combined Chemotherapy ProtocolsCarboplatinHumansJapanPaclitaxel130-nm albumin-bound paclitaxelAlbuminsCarboplatinPaclitaxel

Identifiers

PMID31649134
PMCPMC7288639

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.